Key Takeaways
- Vestal Point Capital, a firm managing $5.47 billion, held none of its Abbott Laboratories, Revolution Medicines or BioCryst Pharmaceuticals shares by Sept. 30, its latest 13F shows.
- Its two largest positions at Sept. 30 were Abivax and Neurocrine Biosciences, and it added to both in the quarter.
- Over the past year, analysts cut their average Abbott target, more than tripled their Revolution Medicines target, and left their BioCryst target flat at nearly 3x the stock price.
- Revolution Medicines has the strongest case of the three. It has an approved drug, and even its lowest analyst target sits above today’s price.
Vestal Point Capital’s 13F for the quarter ended Sept. 30, filed Nov. 16, shows it no longer owns Abbott Laboratories (ABT), Revolution Medicines (RVMD) or BioCryst Pharmaceuticals (BCRX). The firm manages $5.47 billion.
Abbott’s targets have come down for a year
Abbott was the biggest of the three. At June 30 the fund held 1.40 million shares worth $127 million, or 3.0% of its 13F stocks. By Sept. 30 it held none, and Abbott has gained 4% since then.
On Oct. 21, Abbott reported third-quarter adjusted EPS of $1.42 on revenue of $13.01 billion. Revenue grew 14.5%, or 7.0% on a comparable basis. Management reaffirmed its 2026 adjusted EPS guidance of $5.50-$5.55 but lowered its full-year comparable sales growth outlook to 6%. Abbott also announced plans to separate its nutrition business into its own public company.
Analysts have been cutting their targets for a year:

Over the past year the average target fell to $119.60 from $144.47. That’s 16% above the stock’s $103 price, and the lowest target is $100. Abbott trades at about 18x forward earnings. With targets still falling, I don’t see much in the Street’s numbers that would push that multiple higher.
TIKR tracks 28 analysts on Abbott Laboratories. How many say “Buy”?
See the full breakdown of Buy, Hold, and Sell ratings on Abbott Laboratories, along with Wall Street’s revenue and earnings estimates, all in one place. More than 500,000 investors use TIKR to research stocks like this one. See Abbott Laboratories’ Analyst Ratings
Revolution Medicines’ targets more than tripled
Revolution Medicines went the other way. Vestal Point held 450,000 shares worth $84 million at June 30, 2.0% of its 13F stocks, and none by Sept. 30.
The FDA approved RASONQUE (daraxonrasib) for previously treated metastatic pancreatic cancer in August, and the European Commission approved it on Nov. 16. Royalty Pharma has estimated the drug’s peak sales at $11 billion. Analysts raised their targets as the drug moved toward approval:

The average target more than tripled over the past year, to $274.68 from $81.15. That’s 70% above today’s $161.20, and even the lowest target, $179, is above the price. The stock has still fallen 21% since Sept. 30. At a $34.87 billion market value, it’s priced at a bit over 3x Royalty Pharma’s peak-sales estimate.
BioCryst’s target hasn’t budged
BioCryst was the smallest of the three. The fund held 8.30 million shares worth $83 million at June 30, or 1.9% of its 13F stocks, and none by Sept. 30. The stock is down 13% since. Its chart shows how little the Street’s view has changed:

The average target is $20.45, against $20.40 a year ago. Over the same year the stock closed between $6.24 and $11.11. So the average target is 183% above today’s $7.22, and even the lowest target, $11, is about where the stock’s best close of the year was. At about 11x forward earnings, BioCryst looks cheap. But when the Street’s target has sat at nearly 3x the price for a full year, I’d give the market’s skepticism some weight.
Its two biggest bets got bigger
The same filing shows that Vestal Point’s two largest positions both grew in the third quarter. Abivax (ABVX) was the largest at Sept. 30: 3.96 million shares worth $392 million, or 10.1% of its 13F stocks, after a 69% jump in the share count. Neurocrine Biosciences (NBIX) was No. 2, with 2.50 million shares worth $355 million, or 9.2%. That’s 33% more shares than at June 30. Since Sept. 30, Abivax has fallen 26% and Neurocrine has gained 6%. Analysts’ average targets sit 123% above Abivax’s price and 39% above Neurocrine’s.
Revolution Medicines is the one I’d still own
If I could buy only one of the three today, it would be Revolution Medicines. It has an approved drug in the US and Europe, its analyst targets rose all year, and even its lowest target is above today’s price. Abbott’s targets have been falling, and BioCryst’s targets haven’t won the market over in a year.
Revolution Medicines doesn’t make money yet, so its stock price depends on how fast RASONQUE sells. Its fourth-quarter report, due early next year, will show the first full quarter of US sales since the approval. Vestal Point’s next 13F is due in mid-February.
So what is Abbott stock actually worth?
TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what Abbott could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!